Polyethylene glycol modified Bi nano photothermal conversion material as well as preparation method and application thereof
A photothermal conversion material, polyethylene glycol technology, applied in the field of biomedicine, can solve the problems of complex synthesis process, photothermal conversion performance, photothermal stability and biological safety to be improved, and achieves low cytotoxicity, ideal Photothermal treatment effect, strong absorption effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Example Embodiment
[0028] Specific embodiment 1: This embodiment is a polyethylene glycol-modified bismuth nano-photothermal conversion material, which is prepared by using surfactant, bismuth salt, polyacrylamine hydrochloride aqueous solution, polyacrylic acid aqueous solution and crosslinking agent as raw materials The bismuth nano-photothermal conversion material modified by polyethylene glycol has a particle size of 20 nm to 200 nm, and the bismuth nano-photothermal conversion material modified by polyethylene glycol has a photothermal conversion efficiency of 25% to 35%. .
[0029] The preparation of the polyethylene glycol-modified bismuth nano-photothermal conversion material in this embodiment is carried out according to the following steps:
[0030] 1. Add the surfactant to the solvent, mix well under the condition of mechanical stirring, then add the bismuth salt to it, continue to stir and mix uniformly to obtain a reaction mixture, heat the reaction mixture from room temperature to 50℃~1...
Example Embodiment
[0033] Specific embodiment two: this embodiment is different from specific embodiment one in that: the surfactant is one or a mixture of several of α-D-glucose, maltose, ribose and polyvinylpyrrolidone PVP; The solvent is one or a mixture of 1,2-propylene glycol, ethylene glycol and water; the bismuth salt is one or a mixture of several of bismuth nitrate, bismuth acetate and bismuth chloride; the reduction The agent is one or a mixture of morpholine borane solution, sodium borohydride solution and hydroxylamine solution; the concentration of the reducing agent is (10-40) mg / mL; the crosslinking agent A is 1 -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride solution and glutaraldehyde solution one or two mixtures; the crosslinking agent B is 1-(3- One or a mixture of dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride solution and glutaraldehyde solution. Others are the same as the first embodiment.
Example Embodiment
[0034] Specific implementation mode 3: In this embodiment, a method for preparing a polyethylene glycol-modified bismuth nano-photothermal conversion material is performed according to the following steps:
[0035] 1. Add the surfactant to the solvent, mix well under the condition of mechanical stirring, then add the bismuth salt to it, continue to stir and mix uniformly to obtain a reaction mixture, heat the reaction mixture from room temperature to 50℃~150℃, Add reducing agent to the reaction mixture under the condition of 50℃~150℃, react for 0.5min~5min, after the reaction, put it in an ice bath to cool to room temperature, centrifuge and wash 1~5 times, collect the sample and freeze dry to obtain bismuth Nanoparticle materials; the mass ratio of the bismuth salt to the surfactant is 1: (10-30); the mass ratio of the bismuth salt to the solvent is 1 g: (150-250) mL; the reaction mixture is The volume ratio of reducing agent is 1:(0.1~0.2);
[0036] 2. Dissolve the bismuth nanop...
PUM
Property | Measurement | Unit |
---|---|---|
Particle size | aaaaa | aaaaa |
Concentration | aaaaa | aaaaa |
Concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap